EMEA-002941-PIP01-20-M02
Table of contents
Key facts
| Invented name |
Nuvaxovid
|
| Active substance |
Severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine/ matrix-M1 adjuvant (NVX-CoV2373)
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0250/2022
|
| PIP number |
EMEA-002941-PIP01-20-M02
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Prevention of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Novavax CZ, a.s.
Anna Hanzlikova |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|